Novartis: Stop the Attack on Generic Medicines

September 11, 2012

Swiss pharmaceutical company Novartis heads to the Indian Supreme Court today in New Delhi, in a final bid to undermine a key public health safeguard in Indian patent law specifically designed to prevent drug companies from abusive patenting practices that keep medicine prices high. If successful, the move would have a devastating impact on access to essential medicines across the developing world, according to the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF), which relies on affordable generic drugs produced in India to carry out its work in 68 countries. 

For more information, visit www.msfaccess.org/stopnovartis

 

Tags: Access to Medicines

Podcast » A Doctor Returns to Somaliland

Video » Jordan: Shattered Lives in the Middle East

Briefing Documents » Niger 2013: Tackling the Deadly Combination of Malaria and Malnutrition

Slideshow » Surviving Two Years of Treatment for Drug-Resistant TB in Kyrgyzstan

Special Report » Healing Iraqis: The Challenges of Providing Mental Health Care in Iraq

About Us | Field News | Contact Us | Donate | MSF Offices Worldwide

This site is maintained by the U.S. section of Doctors Without Borders/Médecins Sans Frontières (MSF), an international independent medical humanitarian organization that delivers emergency aid to people affected by armed conflict, epidemics, natural and man-made disasters, and exclusion from health care. © 2013 MSF All rights reserved.

Doctors Without Borders is approved by the Internal Revenue Service as a 501 (C) (3) tax-exempt organization, and all donations are tax deductible to the extent provided by law. Doctors Without Borders Federal Identification Number (EIN) is 13-3433452.

MSF-USA Association | Copyright Statement | Privacy Policy

333 7th Avenue, New York, NY 10001-5004. Phone: 212-679-6800